Brexpiprazole in Patients With Schizophrenia

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 12% of the time (422 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patient hasthe patientpatient iscriteria theterm
  Phrases that lowered it: efficacyinvestigatorabnormalsafetyecg
• Sponsor's past termination rate: 18% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Drug's FAERS reports with a death: 0% (lowers risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor's past trials: 50 (lowers risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 15 (lowers risk) · Sponsor's track record
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Maximum age: 65 (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 0 (raises risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Brexpiprazole in Patients With Acute Schizophrenia NCT01810380 · started 2013 · scored riskier than 24% of active trials completed
• A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia NCT05326347 · started 2022 · scored riskier than 20% of active trials completed
• Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder NCT01944969 · started 2013 · scored riskier than 50% of active trials terminated
• Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia NCT02892422 · started 2016 · scored riskier than 44% of active trials completed
• Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia NCT01668797 · started 2012 · scored riskier than 23% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.